Highlights Neuren Pharmaceuticals Limited

Equities

NEU

NZNEUE0001S8

Market Closed - Australian S.E. Other stock markets 07:10:13 28/06/2024 BST			5-day change	1st Jan Change
21.27 ^AUD	+3.15%		+6.35%	-14.82%

05-28	Transcript : Neuren Pharmaceuticals Limited - Shareholder/Analyst Call
05-27	Neuren Phase 2 Trial Shows Significant Improvements in Pitt Hopkins Syndrome	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Neuren Phase 2 Trial Shows Significant Improvements in Pitt Hopkins Syndrome	05-27	CI
Neuren Pharmaceuticals Partner Acadia Pharmaceuticals Posts US DAYBUE Sales of $75.9 Million	05-09	MT
Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada	04-23	MT
Neuren Pharmaceuticals Limited Provides Sales Guidance for the First Quarter and Full Year 2024	02-29	CI
Neuren Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
Neuren Pharmaceuticals Limited Reiterates Net Sales Guidance for the Third Quarter of 2023	28/08/23	CI
Neuren Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended June 30, 2023	28/08/23	CI
Neuren Pharmaceuticals Jumps 17% After Global Expansion of DAYBUE Partnership	14/07/23	MT
Neuren Pharmaceuticals' License Partner Launches Neurological Drug in the US	18/04/23	MT
U.S. FDA approves Acadia's Rett syndrome drug (March 10)	11/03/23	RE
Neuren Pharmaceuticals Appoints Joe Basile to Board of Directors	01/03/23	CI
Neuren Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23/02/23	CI
Neuren Pharmaceuticals Limited Announces Prader-Willi Syndrome IND for NNZ-2591 Approval by FDA	22/01/23	CI
Neuren Pharmaceuticals Advances Regulatory Approvals and Clinical Trials for Neurological Drug	26/12/22	MT
Neuren Pharmaceuticals Submits Investigational New Drug & First Patients Complete Phase 2 Trials	22/12/22	CI
Neuren Pharmaceuticals Receives $10 Million Milestone Payment	20/10/22	MT
US FDA Accepts Neuren Pharmaceuticals' Licensed Drug for Use in Rhett Syndrome; Shares Rise 4%	13/09/22	MT
Neuren Pharmaceuticals Reports Rett Syndrome New Drug Application Accepted for Priority Review by US Food and Drug Administration	13/09/22	CI
Neuren Pharmaceuticals Narrows H1 Net Loss by 11%	24/08/22	MT
Neuren Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended June 30, 2022	24/08/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Neuren Pharmaceuticals Limited

Equities

NEU

NZNEUE0001S8

Highlights

Filters